Follow
Annexin Pharmaceuticals AB
Nasdaq First North Sweden (Sweden)
Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.
Sector:
HEALTH CARE
>
Biotechnology
Sector:
TECHNOLOGY
New issue
Price
1.15 SEK
Subscription period
07 Feb - 21 Feb 2020
View Details
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Show archived
Type
Ticker
ISIN
Market
SHARE
ANNX
SE0009664154
Nasdaq First North Sweden
Sweden (SE)
Details of share in Annexin Pharmaceuticals AB with ticker ANNX
Status
Active
Order book id
Amount of instruments
17 683 632
Par value
1.2000
Market cap
Currency
SEK
Segment
First North
First trading date
19 Apr 2017
Terms
Type
Price
Pre-money valuation
Time
IPO
16.50 SEK
47.4M SEK
06 Mar - 23 Mar 2017
IPO in Annexin Pharmaceuticals AB
Market
Nasdaq First North Sweden
Subscription period
06 Mar - 23 Mar 2017
Subscription price
82.50 SEK
Price per share
16.50 SEK
Target to raise
54 500 000 SEK
Types
Pre-money valuation
47 400 000 SEK
Subscription block size
Minimum subscription
60
Record date
Offer status
Closed
Listing status
Listed
First trading date
19 Apr 2017
Issue terms
Type
Price
Pre-money valuation
Time
Exercise
23.00 SEK
-
20 Nov - 01 Dec 2017
Option exercise terms for ANNX TO1
Market
Nasdaq First North Sweden
Exercise period(s)
20 Nov - 01 Dec 2017
Exercise price
23.00 SEK
Status
Closed
Issue terms
Type
Price
Pre-money valuation
Time
New issue
4.40 SEK
26M SEK
02 May - 17 May 2018
Share issue in Annexin Pharmaceuticals AB
Market
Nasdaq First North Sweden
Subscription period
02 May - 17 May 2018
Subscription price
8.80 SEK
Price per share
4.40 SEK
Target to raise
52 000 000 SEK
Types
Share issue
Pre-money valuation
26 000 000 SEK
Subscription block size
Minimum subscription
Record date
Offer status
Closed
Listing status
Listed
Issue terms
Pre-emption 2:1. One (1) existing share on the record date gives one (1) unit right and one (1) unit right gives the right to subscribe one (1) Unit. One (1) unit consists of two (2) shares and one (1) free of charge warrants of series TO2.
Type
Price
Pre-money valuation
Time
Exercise
4.40 SEK
-
04 Mar - 15 Mar 2019
Option exercise terms for ANNX TO2
Market
Nasdaq First North Sweden
Exercise period(s)
04 Mar - 15 Mar 2019
Exercise price
4.40 SEK
Status
Closed
Issue terms
One (1) warrant of series TO2 (with ISIN code SE0011090232) entitles the holder to subscribe for one (1) new share in the Company during the period 4 - 15 March 2019 to 4.40 SEK per share.
Type
Price
Pre-money valuation
Time
New issue
1.15 SEK
20.3M SEK
07 Feb - 21 Feb 2020
Share issue in Annexin Pharmaceuticals AB
Market
Nasdaq First North Sweden
Subscription period
07 Feb - 21 Feb 2020
Subscription price
1.15 SEK
Price per share
1.15 SEK
Target to raise
61 000 000 SEK
Types
Share issue
Pre-money valuation
20 300 000 SEK
Subscription block size
Minimum subscription
Record date
04 Feb 2020
Offer status
Active
Listing status
Listed
 
Issue terms
The person who, on the record day on February 4, 2020, is included in the share book kept by Euroclear Sweden AB, has the right to subscribe for new shares in the Rights Issue in relation to previous holdings. One (1) existing share held on record date on February 4, 2020, entitles to three (3) subscription rights. One (1) subscription right entitles the holder to subscribe for one (1) new share.
Comments for offer & related information
The company shall issue a maximum of 53 050 896 shares.
Annexin has received subscription commitments of approximately SEK 30.9 million and issue guarantees of approximately SEK 30.1 million, corresponding to 100 percent of the Rights Issue. Subscription commitments have been provided by existing owners, the Board and management and issue guarantees have been provided by a consortium of external investors and existing shareholders.
Type
Ticker
ISIN
Market
SHARE
ANNX
SE0009664154
Nasdaq First North Sweden
Sweden (SE)
Details of share in Annexin Pharmaceuticals AB with ticker ANNX
Status
Active
Order book id
Amount of instruments
17 683 632
Par value
1.2000
Market cap
Currency
SEK
Segment
First North
First trading date
19 Apr 2017
Terms
Type
Price
Pre-money valuation
Time
IPO
16.50 SEK
47.4M SEK
06 Mar - 23 Mar 2017
IPO in Annexin Pharmaceuticals AB
Market
Nasdaq First North Sweden
Subscription period
06 Mar - 23 Mar 2017
Subscription price
82.50 SEK
Price per share
16.50 SEK
Target to raise
54 500 000 SEK
Types
Pre-money valuation
47 400 000 SEK
Subscription block size
Minimum subscription
60
Record date
Offer status
Closed
Listing status
Listed
First trading date
19 Apr 2017
Issue terms
Type
Price
Pre-money valuation
Time
New issue
4.40 SEK
26M SEK
02 May - 17 May 2018
Share issue in Annexin Pharmaceuticals AB
Market
Nasdaq First North Sweden
Subscription period
02 May - 17 May 2018
Subscription price
8.80 SEK
Price per share
4.40 SEK
Target to raise
52 000 000 SEK
Types
Share issue
Pre-money valuation
26 000 000 SEK
Subscription block size
Minimum subscription
Record date
Offer status
Closed
Listing status
Listed
Issue terms
Pre-emption 2:1. One (1) existing share on the record date gives one (1) unit right and one (1) unit right gives the right to subscribe one (1) Unit. One (1) unit consists of two (2) shares and one (1) free of charge warrants of series TO2.
Type
Price
Pre-money valuation
Time
New issue
1.15 SEK
20.3M SEK
07 Feb - 21 Feb 2020
Share issue in Annexin Pharmaceuticals AB
Market
Nasdaq First North Sweden
Subscription period
07 Feb - 21 Feb 2020
Subscription price
1.15 SEK
Price per share
1.15 SEK
Target to raise
61 000 000 SEK
Types
Share issue
Pre-money valuation
20 300 000 SEK
Subscription block size
Minimum subscription
Record date
04 Feb 2020
Offer status
Active
Listing status
Listed
 
Issue terms
The person who, on the record day on February 4, 2020, is included in the share book kept by Euroclear Sweden AB, has the right to subscribe for new shares in the Rights Issue in relation to previous holdings. One (1) existing share held on record date on February 4, 2020, entitles to three (3) subscription rights. One (1) subscription right entitles the holder to subscribe for one (1) new share.
Comments for offer & related information
The company shall issue a maximum of 53 050 896 shares.
Annexin has received subscription commitments of approximately SEK 30.9 million and issue guarantees of approximately SEK 30.1 million, corresponding to 100 percent of the Rights Issue. Subscription commitments have been provided by existing owners, the Board and management and issue guarantees have been provided by a consortium of external investors and existing shareholders.
Type
Ticker
ISIN
Market
OPTION
ANNX TO1
SE0009664196
Nasdaq First North Sweden
Sweden (SE)
Details of option in Annexin Pharmaceuticals AB with ticker ANNX TO1
Status
Archived
Order book id
Amount of instruments
Market cap
Currency
SEK
First trading date
Terms
Type
Price
Pre-money valuation
Time
Exercise
23.00 SEK
-
20 Nov - 01 Dec 2017
Option exercise terms for ANNX TO1
Market
Nasdaq First North Sweden
Exercise period(s)
20 Nov - 01 Dec 2017
Exercise price
23.00 SEK
Status
Closed
Issue terms
Type
Ticker
ISIN
Market
OPTION
ANNX TO2
SE0011090232
Nasdaq First North Sweden
Sweden (SE)
Details of option in Annexin Pharmaceuticals AB with ticker ANNX TO2
Status
Archived
Order book id
157038
Amount of instruments
5 894 544
Market cap
Currency
SEK
Segment
First North
First trading date
Terms
One (1) warrant of series TO2 (with ISIN code SE0011090232) entitles the holder to subscribe for one (1) new share in the Company during the period 4 - 15 March 2019 to 4.40 SEK per share.
Type
Price
Pre-money valuation
Time
Exercise
4.40 SEK
-
04 Mar - 15 Mar 2019
Option exercise terms for ANNX TO2
Market
Nasdaq First North Sweden
Exercise period(s)
04 Mar - 15 Mar 2019
Exercise price
4.40 SEK
Status
Closed
Issue terms
One (1) warrant of series TO2 (with ISIN code SE0011090232) entitles the holder to subscribe for one (1) new share in the Company during the period 4 - 15 March 2019 to 4.40 SEK per share.
People
Number of Employees
4 people
Jamal El Mosleh
CEO
Carl-Fredrik Lindner
Chairman of the board
Johan Frostegård
Board member
Gisela Sitbon
Board member
Anders Haegerstrand
Board member
Lena Torlegård
Board member
Carl-Fredrik Lindner
Board member
Company Details
Sector
HEALTH CARE, TECHNOLOGY

Address
Norrtullsg 6
Zip code
113 29
City/district
Stockholm
Country
Sweden (SE)
Registration number
556960-9539
LEI code
5493000JP703HGPJEX27
First trade date
19 Apr 2017
Registration date
06 Feb 2014
Short name
Annexin Pharmaceuticals

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date